Skip to main content

Ovarian Cancer

Niraparib plus Bevacizumab Combination Leads to Improved PFS Without Cumulative Toxicity in Advanced Ovarian Cancer

Adding Olaparib to Bevacizumab as Maintenance Extends PFS in Newly Diagnosed Advanced Ovarian Cancer

PARP Inhibitors in Ovarian Cancer: Choice May Depend on Treatment Setting, Mutation Status, and Side-Effect Profile

Time to First Subsequent Therapy Longer in Patients with Advanced Ovarian Cancer Who Are Treated with Niraparib

Zejula Receives New Indication as Maintenance Treatment for Patients with Advanced Ovarian Cancer

Improving Patient Access to Biologics: Q&A with Melissa Paige (Part 2 of 2)

CMS Covers Telehealth During Emergency Declaration

Remote Patient Monitoring Is on the Upswing, with Promising Outcomes Data

Ovarian Cancer Remains Deadly, Rates Declining Slowly

Portal Use by Patients with Cancer Is Modest

7
8
9
10
11
12
13

Page 10 of 13
Results 91 - 100 of 125